Abstract: A measles vaccine virus AIK-C strain comprises genomic RNA that produces by reverse transcription cDNA having a specific nucleotide sequence indicative of the viral genomic RNA in the seed virus for measles vaccine or measles virus vaccine. The complete sequence of 15,894 nucleotides has been determined.
Abstract: The sequences encoding two isoforms of human cellular retinoid acid binding proteins, CRABP-I and CRABP-II, have been cloned and sequenced and are set forth with their corresponding amino acid sequences. The identification of human CRABP nucleic and amino acid sequences provides the basis for the construction of recombinant human CRABP vectors and expression constructs. Human CRABP can also be synthesized or produced ex vivo, e.g. in bacterial or other production systems. Ligand binding assays, including recombinant and chimeric receptor reporter assays, and direct and competition hybridization assays employing the human CRABP sequences herein described can be used to test drugs for retinoid induction and tissue specificity for pathologies in which retinoids are implicated. Immunoassays utilizing antibodies or binding fragments produced to human CRABP can also be used to test patient tissues for the presence and levels of CRABP for diagnosis and to monitor treatment.
Type:
Grant
Filed:
June 6, 1995
Date of Patent:
August 5, 1997
Assignee:
The Regents Of The University Of Michigan
Inventors:
Anders Astrom, John J. Voorhees, Ulrika Pettersson, Amir Tavakkol
Abstract: Disclosed are (1) nucleic acid and amino acid sequences for a novel morphogenic protein; (2) methods for producing and expressing the protein in a biologically active form; and (3) methods for utilizing the protein to induce tissue morphogenesis in a mammal, including methods for increasing a progenitor cell population in a mammal, methods for stimulating progenitor cells to differentiate and maintain their differentiated phenotype in vivo or in vitro, methods for inducing tissue-specific growth in vivo and methods for the replacement of diseased or damaged tissue in vivo.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
July 29, 1997
Assignee:
Creative BioMolecules, Inc.
Inventors:
Hermann Oppermann, Engin Ozkaynak, Thangavel Kuberasampath, David C. Rueger, Roy H. L. Pang, Charles M. Cohen
Abstract: The present invention relates to methods of cleaving phosphorothioate oligonucleotides. In particular, it relates to the use of certain restriction endonucleases to cleave phosphorothioate oligonucleotides which contain restriction endonuclease recognition sequences. These restriction sequences can be used to facilitate the cleavage of relatively cleavage resistant phosphorothioate oligonucleotides thus facilitating their separation and purification after synthesis.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
July 29, 1997
Assignee:
Gen-Probe Incorporated
Inventors:
David Bruce Lackey, Nanibhushan Dattagupta, Daniel Louis Kacian
Abstract: A process for the preparation of oligoribonucleotides of the formula ##STR1## in which n, L, BB, W, T, Y', U, C.sup.1 and C.sup.2 are as defined in the description, by solid-phase synthesis is described, as are intermediates of the oligoribonucleotides.
Type:
Grant
Filed:
November 3, 1994
Date of Patent:
July 29, 1997
Assignee:
Hoechst Aktiengesellschaft
Inventors:
Wolfgang Pfleiderer, Ralf Schnell, Stephan Matysiak
Abstract: A drug delivery virion which contains an expression system for the desired protein active ingredient packaged in an envelope derived from a retrovirus is especially useful in administering materials which need to cross cell membranes in order to serve their function.
Abstract: Disclosed are (1) nucleic acid and amino acid sequences for a novel morphogenic protein; (2) methods for producing and expressing the protein in a biologically active form; and (3) methods for utilizing the protein to induce tissue morphogenesis in a mammal, including methods for increasing a progenitor cell population in a mammal, methods for stimulating progenitor cells to differentiate and maintain their differentiated phenotype in vivo or in vitro, methods for inducing tissue-specific growth in vivo and methods for the replacement of diseased or damaged tissue in vivo.
Abstract: Disclosed is an infective lambdoid bacteriophage which includes a protein construct comprising a genetically modified major tail protein truncated at its carboxy terminus, and a target molecule peptide bonded to the carboxy terminus of the tail protein. Also disclosed are nucleic acids encoding the construct and methods of detecting a molecule-of-interest in a solution and of detecting a cell which produces a molecule-of-interest.
Type:
Grant
Filed:
August 31, 1994
Date of Patent:
July 22, 1997
Assignee:
SymBioTech, Inc.
Inventors:
Bryan L. Ray, Edmund C. C. Lin, Roberto Crea
Abstract: The promoter region of the A. Gossypii gene which encodes translation elongation factor EF-1.alpha. is described. The promoter can be employed for protein synthesis.
Type:
Grant
Filed:
October 26, 1994
Date of Patent:
July 22, 1997
Assignee:
BASF Aktiengesellschaft
Inventors:
Roland Kurth, Peter Philippsen, Sabine Steiner, Martin C. Wright
Abstract: The human monoclonal antibody to the glycoprotein gpIII of varicella zoster virus (VZV), and hybridoma producing same, are provided. The hybridoma is obtained by immunizing human lymphocytes with gpIII antigen in the presence of a mitogen, and selecting a monoclonal antibody which reacts with a cell monolayer ELISA plate but substantially does not react with a cell homogenate ELISA plate.
Abstract: Disclosed are improved aqueous processes and compositions for obtaining a "stonewashed", look in colored fabric while reducing the amount of redeposition of colorant onto the fabric, as well as the fabrics produced from these methods. In particular, the disclosed methods as directed to contacting fabrics with fungal cellulase composition which is substantially free of CBH type components. Fabrics so treated show reduced redeposition of colorant.
Type:
Grant
Filed:
September 30, 1992
Date of Patent:
July 22, 1997
Assignee:
Genencor International, Inc.
Inventors:
Kathleen A. Clarkson, Edmund Larenas, Geoffrey Weiss, Benjamin S. Bower
Abstract: Disclosed herein are fully impaired consensus Kozak sequences which are most typically used with dominant selectable markers of transcriptional cassettes which are a part of an expression vector. These vectors are most typically utilized in the expression of proteins in mammalian expression systems. As defined, disclosed and claimed herein, a "fully impaired consensus Kozak" comprises the following sequence: ##STR1## where: Nat nucleotides 2,3,8 and 9 is a nucleotide selected from the group consisting of adenme (A), quanine (G), cytosine (C) or thymine (T)/uracil (U); Nat nucleotides 1 and 7 is a pyrimidine nucleotide, ie C or T/U; "ATG" is a codon encoding for the amino acid methionine, the so-called "start" codon; and -3 and +1 are directional reference points vis-a-vis ATG, ie -3 is meant to indicate three nucleotides upstream of ATG and +1 is meant to indicate one nucleotide downstream of ATG. Dominant selectable markers further comprising artificial intronic insertion regions are further disclosed.
Abstract: A novel African Green Monkey Kidney (AGMK) cell line is taught as well as a method for the preparation thereof. The cell line which is free of viable adventitious microbial agents is useful as a substrate for viruses and for the preparation of viral vaccines.
Type:
Grant
Filed:
November 30, 1994
Date of Patent:
July 8, 1997
Assignees:
Dyncorp, National Institutes of Health
Inventors:
Louis Potash, Robert M. Chanock, Robert H. Purcell, Albert Z. Kapikian
Abstract: The present invention relates to the identification of novel nucleic acid molecules and proteins encoded by such nucleic acid molecules or degenerate variants thereof, that participate in the control of mammalian body weight. The nucleic acid molecules of the present invention represent the genes corresponding to the mammalian tub gene, a gene that is involved in the regulation of body weight.
Abstract: Methods of designing or modifying protein structure at the protein or genetic level to produce specified amino-termini in vivo or in vitro are described. The methods can be used to alter the metabolic stability and other properties of the protein or, alternatively, to artificially generate authentic amino-termini in proteins produced through artificial means. The methods are based upon the introduction of the use of artificial ubiquitin-protein fusions, and the discovery that the in vivo half-life of a protein is a function of the amino-terminal amino acid of the protein.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
July 8, 1997
Assignee:
Massachusetts Institute of Technology
Inventors:
Andreas Bachmair, Daniel Finley, Alexander Varshavsky
Abstract: A hybrid vector carrying a first and second DNA segments operationally linked thereto, the first DNA segment encoding a protein capable of cross-linking to the cap structure of mRNA and mediating ribosome-binding, and the second DNA segment encoding a polypeptide or protein, the vector being capable of replication, transcription and translation to express the factor and the polypeptide or protein upon transformation of a eukaryotic host, and the polypeptide or protein being expressed at a level higher than the level of expression thereof in the absence of the first DNA segment. A eukaryotic host is transformed with this hybrid vector. Also disclosed is a method of increasing the synthesis of a polypeptide or protein in a eukaryotic host cell.
Type:
Grant
Filed:
January 19, 1994
Date of Patent:
July 8, 1997
Assignee:
The University of Kentucky Research Foundation
Abstract: A plasmid vector capable of replicating in a Coryneform bacterial cell bearing a base sequence (a) functioning as an promoter in a Coryneform bacterium, a base sequence (b) functioning as an operator downstream from the base sequence (a), a base sequence (c) functioning as a site for ribosome binding in a Coryneform bacterial cell, a base sequence (d) functioning as a translation initiation codon, and a gene to be expressed which is directly ligated with the base sequence (d) and bearing a gene coding for a repressor protein capable of binding to the base sequence (d) functioning as an operator.
Abstract: Modified retroviral vector particles and modified retroviral producer cells producing such particles are provided for facilitating gene therapy procedures involving the transduction of target cells with retroviral vector particles in the presence of complement containing body fluids. The modifications involve genetic alterations to effect the expression by these cells and particles of complement inhibitor activity. The genetic alterations involve the introduction of nucleic acid expression constructs directing the expression of retroviral SU(gp70)/complement inhibitor chimeric proteins into cells from which the producer cells are derived.
Abstract: Novel expression vectors are provided for expressing a fusion glycoprotein. The fusion glycoprotein contains the N-terminal globular domain of a retroviral env surface protein linked to a selected glycopeptide. Truncation glycoproteins as well as insertion glycoproteins are expressed using the vectors.
Type:
Grant
Filed:
August 20, 1993
Date of Patent:
July 1, 1997
Assignee:
The Public Health Research Institute of the City of New York, Inc.
Abstract: Polynucleotide sequences encoding novel cadherin-related polypeptides, designated protocadherins, and variants thereof are provided by the invention as well as methods and materials for the recombinant production of the same. Antibody substances specific for protocadherins are also disclosed as useful for modulating the natural binding and/or regulatory activities of the protocadherins.